BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 26965582)

  • 21. Prognostic Factors Associated With Progression for Advanced-Stage/G1 and G2 Small-Bowel Neuroendocrine Tumors After Multimodal Therapy: Experience From a Tertiary Referral Center.
    Khetan P; Oyewole F; Wolin E; Kim MK; Divino CM
    Pancreas; 2020 Apr; 49(4):509-513. PubMed ID: 32224719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential.
    Camilli M; Papadimitriou K; Nogueira A; Incorvaia L; Galvano A; D'Antonio F; Ferri J; Santini D; Silvestris N; Russo A; Peeters M; Rolfo C
    Expert Rev Gastroenterol Hepatol; 2018 May; 12(5):471-478. PubMed ID: 29629846
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Daskalakis K; Norlén O; Karakatsanis A; Hellman P; Larsson R; Nygren P; Stålberg P
    Endocr Relat Cancer; 2018 Apr; 25(4):471-480. PubMed ID: 29440231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors.
    Sherman SK; Maxwell JE; Carr JC; Wang D; Bellizzi AM; Sue O'Dorisio M; O'Dorisio TM; Howe JR
    Clin Exp Metastasis; 2014 Dec; 31(8):935-44. PubMed ID: 25241033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Number, not size, of mesenteric tumor deposits affects prognosis of small intestinal well-differentiated neuroendocrine tumors.
    Gonzalez RS; Cates JMM; Shi C
    Mod Pathol; 2018 Oct; 31(10):1560-1566. PubMed ID: 29795438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
    Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
    Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Somatic Mutations and Genetic Heterogeneity at the CDKN1B Locus in Small Intestinal Neuroendocrine Tumors.
    Crona J; Gustavsson T; Norlén O; Edfeldt K; Åkerström T; Westin G; Hellman P; Björklund P; Stålberg P
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1428-35. PubMed ID: 25586243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine.
    Simbolo M; Vicentini C; Mafficini A; Fassan M; Pedron S; Corbo V; Mastracci L; Rusev B; Pedrazzani C; Landoni L; Grillo F; Cingarlini S; Rindi G; Luchini C; Scarpa A; Lawlor RT
    Virchows Arch; 2018 Dec; 473(6):709-717. PubMed ID: 30219970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transcriptome analysis of primary sporadic neuroendocrine tumours of the intestine identified three different molecular subgroups.
    Mattiolo P; Gkountakos A; Centonze G; Bevere M; Piccoli P; Ammendola S; Pedrazzani C; Landoni L; Cingarlini S; Milella M; Milione M; Luchini C; Scarpa A; Simbolo M
    Pathol Res Pract; 2023 Aug; 248():154674. PubMed ID: 37454491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GNA15 expression in small intestinal neuroendocrine neoplasia: functional and signalling pathway analyses.
    Zanini S; Giovinazzo F; Alaimo D; Lawrence B; Pfragner R; Bassi C; Modlin I; Kidd M
    Cell Signal; 2015 May; 27(5):899-907. PubMed ID: 25701539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IMP3 expression in small-intestine neuroendocrine neoplasms: a new predictor of recurrence.
    Massironi S; Del Gobbo A; Cavalcoli F; Fiori S; Conte D; Pellegrinelli A; Milione M; Ferrero S
    Endocrine; 2017 Nov; 58(2):360-367. PubMed ID: 28210937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines.
    Hofving T; Arvidsson Y; Almobarak B; Inge L; Pfragner R; Persson M; Stenman G; Kristiansson E; Johanson V; Nilsson O
    Endocr Relat Cancer; 2018 Mar; 25(3):367-380. PubMed ID: 29444910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors.
    Scott AT; Weitz M; Breheny PJ; Ear PH; Darbro B; Brown BJ; Braun TA; Li G; Umesalma S; Kaemmer CA; Maharjan CK; Quelle DE; Bellizzi AM; Chandrasekharan C; Dillon JS; O'Dorisio TM; Howe JR
    Clin Cancer Res; 2020 Apr; 26(8):2011-2021. PubMed ID: 31937620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene network inference and biochemical assessment delineates GPCR pathways and CREB targets in small intestinal neuroendocrine neoplasia.
    Drozdov I; Svejda B; Gustafsson BI; Mane S; Pfragner R; Kidd M; Modlin IM
    PLoS One; 2011; 6(8):e22457. PubMed ID: 21853033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exome Sequencing and CNV Analysis on Chromosome 18 in Small Intestinal Neuroendocrine Tumors: Ruling Out a Suspect?
    Delgado Verdugo A; Crona J; Maharjan R; Hellman P; Westin G; Björklund P
    Horm Metab Res; 2015 Jun; 47(6):452-5. PubMed ID: 25354328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomic landscape of pancreatic neuroendocrine tumors.
    Gebauer N; Schmidt-Werthern C; Bernard V; Feller AC; Keck T; Begum N; Rades D; Lehnert H; Brabant G; Thorns C
    World J Gastroenterol; 2014 Dec; 20(46):17498-506. PubMed ID: 25516664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Somatostatin and chemokine CXCR4 receptor expression in pancreatic adenocarcinoma relative to pancreatic neuroendocrine tumours.
    Kajtazi Y; Kaemmerer D; Sänger J; Schulz S; Lupp A
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2481-2493. PubMed ID: 31451931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Somatostatin Analogs Treated Small Intestinal Neuroendocrine Tumor Patients Circulating MicroRNAs.
    Li SC; Khan M; Caplin M; Meyer T; Öberg K; Giandomenico V
    PLoS One; 2015; 10(5):e0125553. PubMed ID: 25942502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRAF
    Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
    Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
    Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
    Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.